Skip to main content

Table 2 Low ATM expression independently predicts poor disease survival in a multivariate model in the HNBC cohort

From: Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer

Variables P value HR (95%CI)
A   
tATM (low vs high) <0.001 14.16 (5.17-38.83)
Tumor size (T3/4 vs T1/2) <0.001 9.44 (3.26-27.32)
LN status (+ vs -) 0.03 4.35 (1.11-17.01)
LVI (+ vs -) 0.08 2.51 (0.91-6.91)
Grade (3 vs 1/2) 0.48 1.58 (0.44-5.71)
Age (>53 vs <53) 0.51 1.34 (0.56-3.21)
B   
nATM (low vs high) <0.001 7.43 (2.95-18.76)
Tumor size (T3/4 vs T1/2) <0.001 6.39 (2.36-17.30)
LN status (+ vs -) 0.11 2.84 (0.80-10.07)
LVI (+ vs -) 0.07 2.46 (0.92-6.60)
Grade (3 vs 1/2) 0.55 1.47 (0.41-5.25)
Age (>53 vs <53) 0.32 1.55 (0.66-3.66)
C   
csATM (low vs high) <0.001 4.72 (1.95-11.42)
Tumor size (T3/4 vs T1/2) 0,01 3.45 (1.27-9.36)
LN status (+ vs -) 0.24 2.07 (0.61-7.00)
LVI (+ vs -) 0.57 1.33 (0.50-3.55)
Grade (3 vs 1/2) 0.24 2.29 (0.58-9.08)
Age (>53 vs <53) 0.71 1.20 (0.46-3.10)
  1. Independent prognostic value of ATM expression levels (tATM, nATM and csATM) in both malignant tumor and stromal tissues was evaluated in a multivariate model. A multivariate model was created using selected known prognostic factors such as tumor size, lymph node (LN) status, lymphovascular invasion (LVI), grade and age. Cox proportional hazards regression methods were used to calculate P value, hazard ratio (HR) and confidence interval (CI) of each variable in the model. ATM, ataxia telangiectasia mutated; HNBC, hormone-negative breast cancer; tATM, tumor ATM; nATM, tumor nuclear ATM; csATM, cancer-associated stromal ATM.